Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Balance Sheets

v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 45,816,289 $ 7,266,080
Investments 14,395,913 0
Other current assets 78,869 66,433
Total current assets 60,291,071 7,332,513
Operating lease right-of-use asset 0 12,646
Total assets 60,291,071 7,345,159
Current liabilities:    
In-process R and D accrued expenses 3,000,000 0
Accounts payable, other accrued expenses and other current liabilities 2,254,300 1,757,393
Total current liabilities and total liabilities 5,254,300 1,757,393
Commitments and contingencies (Note 9)
Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,102,560 and 2,980,900 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively** [1] 6,103 2,981
Additional paid-in capital 130,787,312 65,805,134
Accumulated other comprehensive income (loss) 35,992 (14,132)
Accumulated deficit (75,792,636) (60,206,217)
Total stockholders’ equity 55,036,771 5,587,766
Total liabilities and stockholders’ equity $ 60,291,071 $ 7,345,159
[1] Information pertaining to number of shares outstanding and per share data gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.